Vanderbilt University Medical Center, Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232-6600.
ACS Chem Neurosci. 2010 Oct 20;1(10):653-4. doi: 10.1021/cn100061r.
Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4% of the adult population (www.who.int/mental_health/management/depression/definition/en/). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental_health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (Demyttenaere K. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13S69-S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.
Saredutant（SR48968）是一种有潜力的新型治疗选择，可用于治疗重度抑郁症（MDD）和广泛性焦虑症（GAD），它是赛诺菲-安万特公司目前正在进行 III 期临床试验的一种药物。MDD 是一种常见的精神障碍，影响全球 1.21 亿人，占成年人口的近 4%（www.who.int/mental_health/management/depression/definition/en/）。MDD 仍然是导致残疾的主要原因之一，超过四分之三的确诊病例有有效的治疗方法（www.who.int/mental_health/management/depression/definition/en/）。然而，尽管 MDD 影响了很大一部分人群，但具有低不良反应发生率的有效治疗选择仍然是制药行业的主要关注点。典型治疗方法的不良反应（胃肠道副作用 1、体重增加、嗜睡/失眠等（Demyttenaere K.（2003）抑郁症的依从性风险因素和预测因素Eur. Neuropshychopharm.13S69-S75））仍然是提前停止或治疗依从性差的主要原因。新的治疗方法必须考虑到这些不良反应，制药行业目前正在寻找具有新作用机制和更好耐受性的药物。
